Here are the DEF 14A proxy statements from X4 Pharmaceuticals, Inc. (XFOR) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow XFOR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full XFOR filings page.
X4 Pharmaceuticals, Inc. is asking stockholders to vote at its virtual 2026 annual meeting on May 11, 2026. The agenda includes electing three Class III directors to serve until 2029, ratifying PricewaterhouseCoopers LLP as auditor for 2026, approving an amended 2017 Equity Incentive Plan that adds 1,500,000 shares for employee and director awards, and a non-binding advisory vote on executive pay. Stockholders of record on March 13, 2026, when 90,919,696 common shares were outstanding, can vote online or by proxy. The proxy describes board structure, committee responsibilities, governance policies, and how compensation and equity awards are determined.